Recruiting

Ergothioneine

Sponsor:

Stanford University

Code:

NCT06487546

Conditions

Esrd

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ergothioneine

Placebo

Study Details

Brief summary:

Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.

Conditions

Esrd

Study ID

NCT06487546

Start date

Apr 1, 2025

Status verified date

Mar, 2026

Completion date

Dec, 2030

Anticipated

Primary completion date

Apr, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • kidney failure receiving hemodialysis or peritoneal dialysis

Exclusion Criteria:

  • blood transfusion within 90 days
  • taking supplements which contain ergothioneine

Study Design

Enrollment

28 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Ergothioneine

Ergothioneine (range 5 mg to 25 mg) oral daily for up to 12 weeks

placebo comparator: Placebo

Matching placebo oral daily for up to 12 weeks

Interventions

Ergothioneine

Participants will receive ergothioneine capsule daily for 12 weeks.

Placebo

Participants will receive placebo capsule daily for 12 weeks.

Primary outcome measure

  • erythrocyte levels of ergothioneine [ Time Frame: weeks 1, 2, 4, 8, and 12 (while taking ergothioneine or placebo); and weeks 16 and 20 (after stopping ergothioneine or placebo) ]

Central Contacts and Locations

Central contacts

Tammy Sirich, MD

650-493-5000tsirich@stanford.edu

Locations

Veterans Affairs Palo Alto

Recruiting

Palo Alto, California, United States, 94304

Contacts

Tammy Sirich

650-493-5000tsirich@stanford.edu

More Information

Sponsor

Stanford University

Last update posted

Apr 1, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Stanford University on 2026-04-01.